ANEBOTCPharmaceutical PreparationsFiscal year ends June 30

Anebulo Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Dec 31, 2025Last filing: 10-Q on Feb 12, 2026

$0.00+0.00 (+75.00%)

Close on Oct 19, 2026

Market cap: $28.76K
P/E (TTM): –
Dividend yield: –

Anebulo Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30
Cash & Equivalents	12	3.09	11	15	20	3.02
Cash & Short-Term Investments	12	3.09	11	15	20	3.02
Prepaid Expenses & Other	0.26	0.41	0.42	1.03	1.67	–
Total Current Assets	12	3.51	12	–	–	3.03
Other Long-Term Assets	0.18	0.57	–	–	–	–
Total Assets	12	4.07	12	16	22	3.03
Accounts Payable	0.22	0.16	0.53	0.38	0.11	–
Accrued Expenses	0.26	0.10	0.53	0.13	0.13	0.02
Total Current Liabilities	–	–	–	–	–	0.22
Total Liabilities	0.49	0.26	1.07	0.51	0.24	0.22
Common Stock	0.04	0.03	0.03	0.02	0.02	0.01
Additional Paid-In Capital	86	69	68	61	60	–
Retained Earnings	-74	-65	-57	-45	-39	-0.18
Shareholders' Equity	12	3.81	11	15	21	-0.17
Total Equity	12	3.81	11	15	21	-0.17
Total Liabilities & Equity	12	4.07	12	16	22	3.03
Shares Outstanding(shares)	41	26	26	23	23	12

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -109.7%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.00
Dividend yield: –